Saturday 17 October 2026
Export BMRN’s income statement to Excel — free account
BioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
54.68
1.37
−2.44%
Follow BMRN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
9.07% | 5.94% | 4.48% | 1.18% | |
Piotroski F-Score |
8 | 5 | 4 | 3 | |
| 7.20% | 4.79% | 3.42% | 0.76% | ||
ROIC |
7.43% | 5.00% | 3.64% | 0.97% | |
Return on Tangible Assets |
12.71% | 8.41% | 5.63% | 2.21% | |
Average Days of Receivables |
93.23 | 102.91 | 101.76 | 113.69 | |
Free Cash Flow per Share |
4.30 | 3.74 | 3.98 | 3.75 | |
Free Cash Flow |
825.79 | 717.02 | 767.06 | 724.81 | |
Capital Expenditures |
(88.18) | (110.97) | (107.19) | (132.28) | |
| Other line items | |||||
Cash ROIC |
10.16% | 8.70% | 7.78% | 6.37% | |
Accounts Receivable Turnover |
3.95 | 4.11 | 3.95 | 3.55 | |
Accounts Payable Turnover |
0.76 | 1.05 | 1.07 | 0.96 | |
Inventory Turnover |
0.45 | 0.57 | 0.60 | 0.52 | |
Average Days of Payables |
504.32 | 386.16 | 380.48 | 451.23 | |
Days of Inventory on Hand |
873.02 | 660.81 | 610.77 | 799.69 | |
Tax Rate |
(0.23) | (0.28) | (0.30) | (0.51) | |
Research and Development Expense of Revenue |
29.19% | 28.62% | 29.05% | 28.99% | |
Selling, General and Administrative Expense of Revenue |
31.46% | 35.79% | 37.17% | 40.17% | |
Share Based Compensation of Revenue |
6.03% | 5.63% | 5.77% | 6.32% | |
Interest Coverage |
57.53 | 37.57 | 13.71 | 1.79 | |
Operating CF/Net income |
1.76 | 2.37 | 3.25 | 11.75 | |
Depreciation/Fixed assets |
0.07 | 0.08 | 0.07 | 0.15 | |
Capex/Depreciation |
(1.14) | (1.48) | (1.53) | (0.89) | |
Revenue per Share |
16.11 | 16.80 | 16.84 | 17.61 | |
Operating CF per Share |
4.76 | 4.32 | 4.54 | 4.43 | |
Capex per Share |
(0.46) | (0.58) | (0.56) | (0.68) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.04 |
Columns are period end dates